CV genotype and “silent” HBV coinfection: Two main risk factors for a more severe liver disease

Sagnelli, E.; Coppola, Nicola; Scolastico, Carlo; Mogavero, Anna Rita; Filippini, Pietro; Piccinino, F

doi:10.1002/jmv.1057

Cited by 109 publications

(93 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of occult B infection in HCV-infected patients in the present study (19.5%) was above the one reported by some authors (9,12) and below the percentages reported by others (21,28,36,38) , which can be as high as 76% (24) . It should be highlighted that the latter studies used PCR for viral DNA detection, a technique which is more sensitive than immunohistochemistry (4,12) .…”

Section: Discussioncontrasting

confidence: 75%

“…The prevalence of co-infection, is about 15%-30%, and 40%-50% when serum and liver tissue are tested, respectively (7,9,13,15,36) and differs with sensibility of test used.…”

Section: Introductionmentioning

confidence: 99%

“…The importance of an association between HBV and HCV lies in the fact that although HBV viral load in occult infection is often low, a greater likelihood of progression to cirrhosis and to HCC is observed when these patients are compared with those infected only with HCV (7,9,36,37) .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil

Branco

Mattos

Coral

et al. 2007

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -The prevalence and consequences of occult HBV infection in patients with chronic liver disease by HCV remain unknown. Aims -To evaluate the prevalence of occult HBV infection in a population of HCV-infected patients with hepatocellular carcinoma. Methods -The serum samples were tested for HBV DNA by nested PCR and liver tissue analysis was carried out using the immunohistochemical technique of 66 HBsAg-negative patients: 26 patients with chronic hepatitis by HCV (group 1), 20 with hepatocellular carcinoma related to chronic infection by HCV (group 2) and 20 with negative viral markers for hepatitis B and C (control group). Results -Occult HBV infection was diagnosed in the liver tissue of 9/46 (19.5%) HCV-infected patients. Prevalence of occult B infection was evaluated in the HCV-infected patients with and without hepatocellular carcinoma, and there were seven (77.7%) of whom from group 2, conferring a 35% prevalence of this group. No serum sample was positive for HBV DNA in the three groups. Conclusion -Occult infection B is frequently detected in liver tissue of HCV-infected patients, especially in cases of hepatocellular carcinoma. However large studies are needed to confi rm that co-infection could determine a worse progress of chronic liver disease in this population.

show abstract

Section: Discussioncontrasting

confidence: 75%

“…The prevalence of co-infection, is about 15%-30%, and 40%-50% when serum and liver tissue are tested, respectively (7,9,13,15,36) and differs with sensibility of test used.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil

Branco

Mattos

Coral

et al. 2007

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7][8][9][10] Instead, very little is known about HBV/HCV acute concurrent infection because only a few case reports are available in the literature. 11,12 Also, little is known about HBV acute infection when it develops in chronic HCV carriers, but the few case reports published on the topic suggest an association with a severe clinical presentation.…”

mentioning

confidence: 99%

HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course

Sagnelli

Coppola

Messina³

et al. 2002

Hepatology

Self Cite

126

View full text Add to dashboard Cite

We enrolled 44 patients with hepatitis B virus (HBV) acute infection, 21 anti-hepatitis C virus (HCV)-positive for at least 1 year (case BC group), 20 anti-HCV-negative (control B group), and 3 with HBV/HCV acute concurrent infection. For each case BC, a subject with chronic HCV infection alone was selected (control C group). At the first observation, 85.7% of patients in case BC group and 85% of those in control B group were HBV-DNA-positive (polymerase chain reaction [PCR]), with a similar trend towards a decrease and negativization in about 20 days; in the case BC group, seroconversion to antibody to hepatitis B e antigen (anti-HBe) was more rapid. HCV-RNA (PCR) was undetectable in all case BC patients but 1, who shortly became negative, whereas 85.7% of subjects in control C group were positive (P < .001). Severe acute hepatitis was more frequent in the case BC group than in the control B group (28.6% vs. 0%, P < .05). Of the 14 patients in the case BC group and of the 16 in the control B group followed up for more than 6 months, 1 in the first and 1 in the second group became hepatitis B surface angiten ( P atients with chronic hepatitis B virus (HBV)/hepatitis C virus (HCV) concurrent infection show a reciprocal inhibition of viral genomes, an association with a severe clinical presentation, and an infrequent response to interferon alfa treatment. 1-10 Instead, very little is known about HBV/HCV acute concurrent infection because only a few case reports are available in the literature. 11,12 Also, little is known about HBV acute infection when it develops in chronic HCV carriers, but the few case reports published on the topic suggest an association with a severe clinical presentation. [13][14][15] Acute HBV infection in chronic HCV carriers may be rather frequent in Italy and in other western countries where drug addicts are numerous, frequently anti-HCVpositive, [16][17][18][19] and infrequently vaccinated against HBV.This article reports the data from our study on the clinical presentation, course of the disease, and HBV/ HCV interaction in 21 HCV chronic carriers who developed HBV acute hepatitis (cases), compared with 20 patients with HBV-related acute hepatitis with no HCV infection (controls) observed in the same period. We also report the data on 3 cases of HBV/HCV acute concurrent infection identified in the same investigation. Patients and MethodsWe enrolled all 44 consecutive patients with HBVrelated acute hepatitis hospitalized in our ward from

show abstract

“…Some studies showed that HBV infection could occur in recipients of livers donated from subjects with anti-HBc but without HBsAg (19,20). That is, anti-HBc, which was initially considered to be an index for the past HBV infection in which all HBV had been cleared, has emerged as a convincing marker of occult hepatitis B (19,(21)(22)(23). Also, several studies showed that the anti-HBc positivity was associated with the development of HCC in patients with HCV-associated chronic liver disease (11,(24)(25)(26), but these associations have not been clearly demonstrated.…”

Section: Introductionmentioning

confidence: 99%

Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: A 12-year prospective study

Tanaka

Nagao²,

Ide³

et al. 2006

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Several studies have reported that antibody to hepatitis B core antigen (anti-HBc) positivity may influence the development of hepatocellular carcinoma (HCC) in chronic hepatitis C patients, but the evidence is still not conclusive. In this study, we examined whether the presence of antiHBc positive was associated with the development of HCC in hepatitis C virus (HCV)-infected subjects among the residents in an HCV hyperepidemic area who were followed up for 12 years. In an HCV hyperendemic area (positive rate of anti-HCV: 23.4%), 509 residents were examined by health screening in 1990. After 12 years of follow-up, we evaluated the risk factors for HCC. The incidence of HCC was compared between anti-HBc positive and anti-HBc negative subjects after 12 years of prospective observation. Univariate and multivariate analyses were conducted to determine risk factors for the development of HCC. The incidence of HCC was significantly higher in the anti-HBc positive group (13 subjects) than in the anti-HBc negative group (0 subjects) (P=0.012). Multivariate analysis identified positivity for antiHBc and HCV RNA, history of icterus, and female gender as independent determinants of the development of HCC. Our findings provide clear evidence in a prospective study that presence of anti-HBc, that is, past hepatitis B virus (HBV) infection, is a risk factor for the development of HCC in HCVinfected people.

show abstract

CV genotype and “silent” HBV coinfection: Two main risk factors for a more severe liver disease

Cited by 109 publications

References 39 publications

Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil

Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis C virus and hepatocellular carcinoma in Brazil

HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course

Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: A 12-year prospective study

Contact Info

Product

Resources

About